Sign in
Taking people in ItalyNo phase

Reviews past records of older adults with spreading colon cancer receiving chemotherapy

Looks back at chemotherapy with antibody treatment in adults 70 and older with colon cancer.

Key facts

Who runs it
Matteo Clavarezza
Where
Genoa and Genova, ItalySee the 2 sites
Trial code
Registry title
COLON ERDERLY LOW DOSE
Status
Recruiting
People taking part
51 people, planned
Started
7 Jul 2026
Expected to end
31 Jul 2027
Type of study
Observational
Record updated
16 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The study looks at people aged 70 or older with metastatic colorectal cancer who have not yet had any treatment for the spread of the disease. They must have MSS, BRAF wild-type tumours and a G8 score of 12 or more.

Age
70 to 99 years
Sex
All sexes can join.
Disease stage
Metastatic colorectal adenocarcinoma (colon cancer that has spread).
Earlier treatment
No treatment yet for the metastatic disease. Earlier (neo)adjuvant treatment with fluoroderivatives, with or without Oxaliplatin, is allowed.
Biomarker or test result
MSS tumour and BRAF WT (wild-type) tumour. G8 score of 12 or more.

Main reasons for not taking part

  • MSI tumours
  • BRAF V600E mutated tumours
  • Not able to have doublet chemotherapy, by clinical decision

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Patients with metastatic colorectal adenocarcinoma not treated with any therapy in the metastatic phase. Previous (neo)-adjuvant treatment with fluoroderivatives with or without Oxaliplatin is permitted
  • Age ≥ 70 years
  • G8 score ≥ 12
  • Patients with colorectal adenocarcinoma MSS
  • Patients with BRAF WT colorectal adenocarcinoma
  • Ability to understand and sign the informed consent form

Who cannot take part

  • Patients not eligible for doublet chemotherapy by clinical decision
  • Patients with MSI tumours
  • Patients with BRAF V600E mutated tumours

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 70 and 99 years old?

This trial is currently available in Italy.

  • E.O. Ospedali GallieraGenoa, ItalyContact: Davide S CorradengoNot yet recruiting
  • E.O. Ospedali GallieraGenova, ItalyContact: Davide CORRADENGOTaking people

About the trial

What the trial wants to find out

In this retrospective observational study, the case series of patients undergoing first-line treatment for metastatic colorectal adenocarcinoma with doublet fixed-dose and reduced-dose chemotherapy in combination with full-dose monoclonal antibody in patients aged 70 years or older is collected.

The group in the trial

  • Retrospective

    PATIENTS AGED 70 YEARS AND OVER IN FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
RETROSPECTIVE OBSERVATIONAL STUDY OF CHEMOTHERAPY IN ELDERLY PATIENTS IN THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
Plain-language title
Reviews past records of older adults with spreading colon cancer receiving chemotherapyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT06840977, who can take part
Record updated
16 July 2026